EGFR TKIs treatments and clinical outcome parameters
| Patient no. | EGFR mutation | Treatment regimen | RR | Starting tratment | PD or SD |
| 1 | ELREA | Afatinib | PR | 30 January 2017 | PD 12 October 2017 |
| 2 | ELREA | Afatinib | PR | 1 April 2016 | PD 11 May 2017 |
| 3 | V769_D770ins AVS | Afatinib | PR | 11 May 2016 | Death (1 December 2016) |
| 4 | ELREA | Afatinib | PR | 17 May 2016 | PD 21 July 2017 |
| 5 | D770_N771ins SVD | Afatinib | PR | 1 May 2016 | PD 21 August 2017 |
| 6 | ELREA | Afatinib | PR | 20 June 2016 | PD 7 June 2017 |
| 7 | ELREA | Gefitinib | SD | 25 June 2016 | PD 7 June 2017 |
| 8 | L858R | Gefitinib | PR | 24 March 2016 | PD 20 January 2017 |
| 9 | L858R+E709K | Gefitinib | SD | 29 December 2016 | PD 4 October 2017 |
| 10 | ELREATS +P753S | Gefitinib | PR | 24 October 2016 | PD 12 September 2017 |
| 11 | L858R | Gefitinib | PR | 6 July 2016 | PD 5 May 2017 |
PD, progression disease; PR, partial response; RR, response rate; SD, stable disease; TKIs, tyrosine kinase inhibitors.